Lipid te AA3-Dlin
Version 1.f985d8e7 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid te AA3-Dlin |
| Synonyms | Lipid -te-AA3-Dlin, Lipid te AA3 Dlin |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCCCOC(=O)CCN1CCN(CCC(=O)OCCCCCCCC/C=C\C/C=C\CCCCC)CC1 |
| Formula | C48H82N2O4 |
| M.Wt | 727.17 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | mRNA-Based Vaccination Drives In Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity-ACS Nano Vol 19-Chenshuang Zhang, William Stewart2, Yilong Teng, Bin Hu, Xiaoyang Xu, Xue-Qing Zhang |
TE AA3-Dlin is an optimized lipid nanoparticle (LNP) carrier designed for mRNA-based cancer immunotherapy, enabling precise in vivo dendritic cell (DC) reprogramming to enhance antitumor immunity. TE AA3-Dlin LNP exhibits superior serum stability, maintaining consistent particle size and low turbidity under physiological conditions, while protecting mRNA from degradation, which is crucial for effective delivery. Functionally, TE AA3-Dlin preferentially targets splenic DCs by leveraging ApoE-enriched protein coronas, facilitating efficient cellular uptake and mRNA expression, as demonstrated by enhanced EGFP signals in DCs.This targeting promotes DC maturation, antigen presentation, and membrane-bound IL-15 expression, activating cytotoxic T lymphocytes (CTLs) for tumor rejection. In models like melanoma and colon carcinoma, it synergizes with checkpoint inhibitors, showing minimal toxicity and robust immunological memory.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →